Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 25.9× sales vs its 132.4× historical median P/S.
Fair value ≈ $89.13 · price $17.42 today
Undervalued · 80% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
@ChadTrades3 I bought this about 5 years ago for around $52/share and this board has been completely dead the entire time. Possibly because no matter what $PRTC and its entities accomplish, the stock is perpetually stuck in purgatory. It never, ever, ever breaks $20.
$PRTC has announced that its founded entity, closely held Seaport Therapeutics, has reported positive proof of concept topline data from portions of its ongoing Phase 1 proof-of-concept clinical trial evaluating GlyphAgo (SPT-320 or Glyph Agomelatine) in generalized anxiety disorder (GAD).
https://biotuesdays.com/2026/04/02/puretechs-seaport-reports-positive-data-from-trial-of-glyphago-in-gad/
$PRTC This ticker is entering a stage where execution quality will overshadow headline narratives. Cost discipline must coexist with targeted investment. Smart capital allocation could unlock optionality not yet reflected. The thesis improves only as operational proof accumulates.
$PRTC has announced the appointment of Robert Lyne as chief executive officer (CEO), and member of the board of directors, effective immediately
https://biotuesdays.com/2025/12/18/puretech-appoints-robert-lyne-as-ceo/
$PRTC (-8.1% pre) PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
https://ooc.bz/l/86630
$PRTC's hub-and-spoke model spins out mature assets (Seaport, Gallop, Celea) to attract external capital, reducing parent R&D burn while retaining equity & royalties. This extends cash runway past 2028 and shifts funding risk to VCs. 🧬 #BiotechStrategy
$PRTC Great piece that accurately captures PRTC's current position. So if you want to refresh your understanding of PRTC or learn about PRTC for the first time, this is essential reading. https://beyondspx.com/quote/PRTC/analysis/puretech-health-unlocking-value-through-de-risked-innovation-and-strategic-spin-outs-prtc
$PRTC Puretech Founded Entity Seaport Therapeutics Doses First Participant In Phase 1 Study Of Glyphago SPT-320 Oral Prodrug Of Agomelatine For Generalized Anxiety Disorder
